Elevated CD56brightNK cell and IFNγ levels in the blood of children with common cold provides a clue for preventing COVID-19

Author:

Chen Zhanpeng,Chen Zhanpeng,Chen Zhanpeng1,Chen Zhanpeng1

Affiliation:

1. Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Diseases, The Third People’s Hospital of Shenzhen

Abstract

Abstract Objective: We aim to detect and compare the levels of natural killer (NK) cells (CD56bright and CD56dim), interleukin (IL)18, interferon (IFN)α, and IFNγ in the blood of children with common colds and healthy children, in order to provide clues for the prevention of coronavirus disease 2019(COVID-19)at the current stage. Study design: A total of 153 children, including 49 with common colds and 104 healthy children, were recruited for this cross-sectional study. The demographic characteristics and lifestyle habits of healthy children and children with common cold are similar. Peripheral venous blood samples were collected by professional nurses for flow cytometry analysis and cytokine determination. Results: We found that compared to healthy children, children with common colds had significantly reduced forced vital capacity (FVC), and increased CD56brightNK cell ratio, and levels of serum IL18 and IFNγ (all P < 0.05). Linear regression analysis showed that the increase in IFNγ level was positively correlated with the increase in CD56brightNK cell, IFNα, and IL18 levels (all P < 0.05). The increase in CD56brightNK cell ratio was positively correlated with the increase in IFNγ and IL18 levels (all P < 0.05). Conclusions: Children may resist common cold by increasing the levels of CD56brightNK cells, IFNγ, and IL18 in their blood, which could be the reason why children are more susceptible to common cold but exhibit stronger immunity against COVID-19. CD56brightNK cells may serve as a crucial breakthrough in addressing the current prevalence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

Publisher

Research Square Platform LLC

Reference47 articles.

1. Organization WH. Weekly epidemiological update on COVID-19–1 September 2023 2023. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-september-2023.

2. Wu J, Deng W, Li S, Yang X. Advances in research on ACE2 as a receptor for 2019-nCoV. Cellular and molecular life sciences: CMLS. 2021;78(2):531 – 44. Epub 2020/08/12. doi: 10.1007/s00018-020-03611-x. PubMed PMID: 32780149; PubMed Central PMCID: PMCPMC7417784.

3. Prevention CfDCa. About COVID-19 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19.html.

4. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection;Hall V;The New England journal of medicine,2022

5. How kids' immune systems can evade COVID;Nogrady B;Nature,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3